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An Inhibitor of the Human UDP-GlcNAc 4-Epimerase
Identified from a Uridine-Based Library:
A Strategy to Inhibit O-Linked Glycosylation
structure-function analysis and compromises our ability
to decipher the important physiological functions these
structures may perform.
Study of O-linked glycosylation has suffered particu-
larly in this regard. The basic ability to inhibit the process
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3 Howard Hughes Medical Institute at will—so crucial to experiments testing the signifi-
cance of O-linked glycans in a particular physiologicalUniversity of California, Berkeley
Berkeley, California 94720 transaction—so far eludes us. While, for the N-linked
modification, abolition of glycosylation by site-directed
mutagenesis of consensus sites in the acceptor protein
represents a routine strategy [5–7], no analogous con-Summary
sensus sequence directing O-linked initiation exists. The
family of transferases catalyzing the initial transfer of anThe biological study of O-linked glycosylation is partic-
ularly problematic, as chemical tools to control this mod- N-acetylgalactosamine (GalNAc) residue from the high-
energy donor, UDP-GalNAc, to a serine or threonine onification are lacking. An inhibitor of the UDP-GlcNAc
4-epimerase that synthesizes UDP-GalNAc, the donor the acceptor protein possesses poorly defined and over-
lapping preferences for the acceptor protein’s sequenceinitiating O-linked glycosylation, would be a powerful
reagent for reversibly inhibiting O-linked glycosyla- [8, 9]. Serines and threonines typically abound near
O-linked sites; their prevalence impedes identificationtion. We synthesized a 1338 member library of uridine
analogs directed to the epimerase by virtue of sub- of a glycan’s precise amino acid host and implies that
loss of a known O-linked locale may simply divert thestrate mimicry. Screening of the library identified an
inhibitor with a Ki value of 11M. Tests against related carbohydrate to a nearby, normally vacant site [10].
Chemical control of O-linked glycosylation in culturedenzymes confirmed the compound’s specificity for the
UDP-GlcNAc 4-epimerase. Inhibitors of a key step of cells is also limited; a solitary reagent, -benzyl GalNAc,
comprises the entire arsenal. This compound serves asO-linked glycan biosynthesis can be discovered from
a directed library screen. Progeny thereof may be pow- an alternative substrate for enzymes that modify the ini-
tial, monoglycosylated protein, curtailing elaboration oferful tools for controlling O-linked glycosylation in cells.
O-linked glycans beyond the monosaccharide GalNAc
[11]. Unfortunately, broad use of -benzyl GalNAc hasIntroduction
been limited because the compound represents a po-
tentially toxic cell culture additive at the millimolar con-The carbohydrate chains that adorn membrane proteins
have emerged as key players in the information transfer centrations required, and allows the protein to retain
its important, proximal GalNAc residue. In contrast, thethat takes place at the cell surface. Leukocyte recruit-
ment to sites of inflammation, cell adhesion to the extra- study of N-linked glycans profits from the glycosylation
inhibitor tunicamycin, a compound originally identifiedcellular matrix during development, and the sperm-egg
recognition that initiates fertilization all demand the ap- for its antiviral properties that blocks the synthesis of
the carbohydrate donor for N-linked glycosylation withpropriate carbohydrate participant [1–3]. Furthermore,
aberrant glycan structures mediate disease states such nanomolar efficiency [12]. In addition, a potent inhibitor
of the solitary oligosaccharyl transferase that initiatesas chronic inflammation and cancer metastasis [4]. De-
spite compelling examples of the physiological roles N-linked glycosylation offers the promise of highly selec-
tive interruption of this posttranslational modificationthat protein-bound saccharides may play, in general,
structure-function correlations for glycans have lagged [13]. The benefit to N-linked glycan research of such
tools has been marked, suggesting to us that an analo-dramatically behind an analogous understanding of the
protein proper. While the techniques of molecular biol- gous chemical tool for O-linked research would prove
valuable.ogy—site directed mutagenesis, gene knockouts, and
As a broad scheme to enhance our ability to analyzethe like—have revolutionized our comprehension of pro-
the functional significance of O-linked protein glycosyla-tein science, oligosaccharide assembly defies the analo-
tion, we therefore sought to develop an inhibitor of thisgous manipulation. Carbohydrate chains are assembled
process. A natural focus might have been the enzyme(s)on either asparagine (N-linked glycosylation) or serine or
responsible for installing the initial monosaccharide,threonine residues of proteins (O-linked glycosylation) in
GalNAc, onto the fledgling glycoprotein. However, thesequences that vary with the efficiency of the glycosylat-
cohort of GalNAc transferases performing this task—8ing enzymes; the glycoprotein product thus is not a
mammalian genes characterized so far—comprised adiscrete structure, but rather an array of glycoforms. The
complicated target [8, 14]. Thus, we looked upstreamheterogeneity that characterizes glycans complicates
to the biosynthesis of UDP-GalNAc, the carbohydrate
donor itself. Our attention centered on the UDP-GlcNAc4 Correspondence: bertozzi@cchem.berkeley.edu
4-epimerase (called 4-epimerase hereafter), which cata-5 Present address: Department of Medicine, Division of Infectious
lyzes the conversion of the common nucleotide sugarDiseases and Geographic Medicine, Stanford University Medical
Center, Stanford, California 94305. UDP-GlcNAc to the O-linked precursor, UDP-GalNAc;
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Figure 1. Biosynthesis of UDP-GalNAc, the Initial Carbohydrate Donor in O-Linked Glycosylation
The major route to cellular UDP-GalNAc is via exogenous Glc and GlcNAc, both of which can be converted to UDP-GlcNAc. Epimerization
at the C-4 position (in red) by our target enzyme, the UDP-GlcNAc 4-epimerase, yields UDP-GalNAc. The same epimerase converts UDP-Glc
to UDP-Gal. Salvage pathways (blue arrows) enable the cell to take up Gal and GalNAc and convert them directly to their UDP-linked derivatives.
inhibiting this conversion would be expected to curtail blockage of the 4-epimerase will provide a flexible tool
for modulating protein glycosylation in any cultured cellO-linked glycosylation altogether (Figure 1). We rea-
soned that since GalNAc expression on proteins is line of interest.
Having identified our target enzyme, our immediatelargely limited to O-linked glycans—its reported incor-
poration into N-linked structures is rare, confined to the task became the efficient design of an inhibitor. To date,
the most potent inhibitors of enzymes operating onterminal elaborations of certain pituitary glycopeptide hor-
mones [15–17]—the effects of our potential UDP-GalNAc UDP-linked carbohydrates have been rationally de-
signed substrate or transition-state analogs [22–26].inhibitor would be appropriately selective. Indeed, ex-
periments by Krieger and coworkers with a Chinese These compounds incorporate the UDP component of
hamster ovary (CHO) cell line deficient in 4-epimerase
activity, the “ldlD” cell line, demonstrate that O-linked
glycans may be inhibited to the exclusion of their
N-linked counterparts [18, 19].
One complication to this simple paradigm should be
noted. Mammalian forms of the 4-epimerase also con-
vert UDP-Glc to UDP-Gal (Figure 1) [20]. While GalNAc
expression is largely limited to O-linked glycans, Gal
participates more widely; it comprises, for example, part
of the LacNAc (Gal1-4GlcNAc) disaccharide commonly
appended as long chains in complex-type N-linked gly-
cans [21]. 4-Epimerase inhibition would then affect both
N- and O-linked structures. Fortunately, nature provides
a safety valve; salvage pathways enable the cell to utilize
the free monosaccharides Gal and GalNAc to generate
their UDP-linked derivatives (Figure 1). By supplying ex-
ogenous Gal to cultured cells treated with inhibitor, we
should selectively impede O-linked glycosylation while
leaving N-linked structures intact (Figure 2). Treatment
with inhibitor without either Gal or GalNAc should trun-
cate complex and hybrid type N-linked structures, and
abolish O-linked glycans altogether. Finally, application
of Gal and GalNAc to inhibitor-treated cells should res-
Figure 2. Expected N- and O-Glycan Structures in the Presence ofcue both types of glycosylation. Experiments using the
a UDP-GlcNAc 4-Epimerase Inhibitor
4-epimerase-deficient ldlD cells yield just this pattern
For each panel, the designation in bold indicates the presence orof data, supporting our choice of target enzyme [18, 19].
absence of exogenous Gal or GalNAc. When only exogenous Gal is
Furthermore, the viability of these cells when exogenous added (lower left panel), selective inhibition of O-linked glycosylation
sugars are limiting supports our hypothesis that 4-epi- should be observed, with N-linked glycans unaffected. Adapted
from [18].merase inhibition would be tolerated. We predict that
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Figure 3. General Strategy for Uridine Library
Synthesis
Aminooxy- and hydrazide-functionalized uri-
dine forms the common library scaffold; vari-
ety is installed by reaction of the uridine deriv-
ative with a library of aldehydes chosen for
their diversity and favorable pharmacological
properties. The selective nature of oxime or
hydrazone formation (indicated in green)
allows the incorporation of a wide array of
functionality on library aldehydes without the
need for protecting groups and their atten-
dant complications. Three different linkers
(indicated in blue) were designed as potential
diphosphate substitutes.
the native substrate, while altering the sugar structure amidst a complex, richly functionalized backdrop. The
technique has been employed in peptide synthesis [27,to abolish turnover or enhance binding. While such strat-
egies have generated inhibitors with potencies in the 28], cell surface engineering [29, 30], and, more recently,
chemical library synthesis [31]. Taking our cue frommicromolar range—affinities that rival those of the sub-
strates—the winning compounds are unsuitable for use these pioneering works, we employed chemoselective
ligation as a facile mechanism to diversify the uridine-in vivo, since their highly polar or even charged struc-
tures would be membrane impermeable. We thus sought based library, and thereby optimize the substituent oc-
cupying the carbohydrate binding pocket of the 4-epi-to develop an expedient method to capitalize on the
inherent binding affinity of the 4-epimerase for its sub- merase. The uridine derivatives were readily generated
on multigram scale, which allowed for tuning of the linkerstrate, while simultaneously optimizing the pharmaco-
logical properties of the potential inhibitor. region to facilitate binding by aldehyde-derived substit-
uents.Our strategy exploited a key chemoselective coupling
between a uridine derivative functionalized at its 5 posi- We report herein the initial phase of this project: the
synthesis and screening of uridine-derived librariestion by an aminooxy or hydrazide group and a diverse
array of commercially available aldehydes, which yielded against the human 4-epimerase. From these libraries a
hit compound designated 1-143 was identified, with athe corresponding oxime- or hydrazone-based libraries
(Figure 3). The highly selective natures of oxime and Ki versus the substrate UDP-Gal of 11 M. In vitro tests
of this compound’s potency against a panel of relatedhydrazone bond formation make them suited for biologi-
cal applications in which specific reactions are desired enzymes demonstrate the specificity of the hit compound
Figure 4. Aminooxy- and Hydrazide-Functionalized Uridine Derivatives Used in Library Synthesis
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Figure 5. Synthesis of 5-Aminooxy-Uridine 1
a, 2,2-dimethoxypropane, TsOH, DMF; b,
Ts2O, pyr, CH2Cl2; c, NHS, DIEA, DMF; d, 90%
TFA/H2O; e, 40% MeNH2/H2O:MeOH (2:1).
for its target enzyme, the 4-epimerase, and suggest that 1 in 38% yield over the five-step synthesis after HPLC
purification.testing of this compound as an inhibitor of O-linked glyco-
sylation in cultured cells would be warranted. The latter two targets, compounds 2 and 3, both de-
rived from 5-aminouridine 11 (Figure 6). Installation of
the nitrogen functionality was achieved by reacting theResults
common intermediate, 5-O-toluenesulfonyl uridine de-
rivative 6, with lithium azide. Ensuing chemistry requiredSynthesis of Aminooxy- and Hydrazide-
the reduction of azidouridine 9 to the amino compound.Functionalized Uridine Derivatives
Interestingly, in our hands 5-azido-2,3-O-isopropyli-Our initial challenge was to design and synthesize ap-
dene uridine (9) was entirely resistant to reduction; thispropriate uridine derivatives (Figure 4). We chose three
experience contrasts with previous reports in which thislinking structures to unite the uridine component with
compound was successfully reduced by hydrogenationits aldehyde partner in order to explore the significance
[22]. Acid hydrolysis of the isopropylidene yielded theof varied length, flexibility, and hydrogen-bonding po-
free azido sugar 10, which we found was easily reducedtential to inhibitor potency. Data of UDP-Gal complexed
to 5-aminouridine 11 by Pd-catalyzed hydrogenation.with the E. coli 4-epimerase reveal hydrogen bonding
The overall yield for production of 5-aminouridine 11interactions between the substrate’s phosphate groups
from free uridine in five steps was 80%, an efficiencyand three amino acid side chains [32]. In our linkers we
that allowed ample production of subsequent uridinesought to incorporate analogous hydrogen bond ac-
derivatives.ceptors; we postulated that the amide and sulfonyl moi-
Synthesis of the second target, 5-aminooxy-glycyl-eties of 2 and 3, respectively, would fulfill this goal (Fig-
uridine 2, was completed by an EDC and HOBt-mediatedure 4). Both carbonyl and sulfonyl groups have been
coupling of the intermediate 5-aminouridine 11 withused successfully as phosphate substitutes [33, 34].
(t-BOC-aminooxy)acetic acid. Deprotection of 12 andIndeed, the sulfonyl benzoyl group’s aptitude as a di-
purification by HPLC afforded 5-aminooxy-glycyl-uri-phosphate mimic has been documented in a 54 nM
dine 2 in 41% yield over the final two steps. Our finalinhibitor of the EGF-receptor protein tyrosine kinase
target, 5-hydrazido-phenylsulfonyl-uridine 3, was also[35]. Because the diversity inherent in our aldehyde col-
prepared using the 5-aminouridine (11) intermediate; inlection made predicting a preferred linker length impos-
this case a coupling with methyl ester 13 installed thesible, we installed corresponding diversity in the linker,
desired linker (Figure 7). The coupled product 14 waschoosing structures ranging from one (1) to six bonds
saponified using lithium hydroxide, then an EDC and(3) between the 5 uridine substituent and the oxime or
HOBt-mediated coupling to t-BOC hydrazide yieldedhydrazone nitrogen. We speculated that compound 2
compound 15. Finally, deprotection and HPLC purifica-would display slightly enhanced flexibility due to the
tion yielded uridine target 3 in 37% yield over four steps.methylene proximal to its aminooxy group.
To achieve the most efficient syntheses of the three
uridine targets, we designed routes using common inter- Synthesis and Characterization
of Uridine-Derived Librariesmediates where it was practical; thus, compounds 1-3
all derived from the activated 5-O-toluenesulfonyl uri- The successful synthesis of uridine derivatives 1-3 and
the purchase of 446 commercially available aldehydesdine derivative 6 (Figure 5). This compound was gener-
ated by treatment of uridine (4) with 2,2-dimethoxypro- provided the building blocks for our library of uridine
conjugates (Figure 4). To determine appropriate reactionpane and TsOH in DMF to afford 2,3-O-isopropylidene
uridine (5) in 89% isolated yield. Tosylation was achieved conditions for library synthesis, we monitored by 1H NMR
a sample of 33 oxime and hydrazone-forming reactions.in routine fashion. To produce the initial uridine target
1, the tosylate was displaced with NHS to yield com- Figure 8 depicts three examples. Reaction progress was
observed by following the disappearance of the alde-pound 7. Two deprotection steps followed, producing
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Figure 6. Synthesis of 5-Aminooxy-Glycyl-
Uridine 2
a, LiN3, DMF; b, 90% TFA/H2O; c, H2, Pd/C,
MeOH; d, (t-BOC-aminooxy)acetic acid, EDC,
HOBt, DMF; e, 40% TFA/CH2Cl2.
hyde proton resonance (typically found between 8.5 and the corresponding appearance of oxime or hydrazone
product (Table 1). The identities of the coupled products11.0 ppm) and the corresponding appearance of oxime
or hydrazone proton resonance (typically between 7.0 were confirmed by mass spectrometry. The presence
of side products precluded this method of yield determi-and 9.5 ppm). The identities of the coupled products
were confirmed by mass spectrometry; stereochemistry nation in several cases, indicated with an asterisk in
Table 1. Dilute concentrations of reagents appeared toabout the oxime or hydrazone double bond was not
determined. Reactions were performed at room temper- affect the coupling negligibly; these reactions were
highly efficient and clean, producing yields of 80% orature, with substrates at 0.1 M in 1% AcOH in d6-DMSO.
We found that most were complete within 12 hr, as better in 85 out of 99 reactions tested. Cases in which
yields lagged often correlated with incomplete dissolu-shown in Figure 8; almost all observed were complete
within 2 days. Hydrazone-forming reactions with uridine tion of the aldehyde in the reaction mixture.
derivative 3 tended to proceed slightly more slowly than
the corresponding oxime formations; three such reac-
tions required 4 days to complete. Of the 33 reactions Screening of Uridine Libraries against
UDPGlcNAc 4-Epimerasefollowed in this manner, all but four afforded yields of
80% or better (Table 1). All products, observed under With the uridine-derived library in hand, we pursued our
larger goal of identifying potential inhibitors of the 4-epimer-these conditions for a total of 7 days, were found to
be stable for the duration of the experiment. We thus ase. The 1338 library compounds were screened against
the 4-epimerase using a coupled-enzyme system with aobserved that these coupling reactions were highly effi-
cient, confirming their utility for the large-scale library spectrophotometric readout (Figure 9). The compounds
were assayed at 100M, in the presence of 100M—theproduction we planned.
Limited quantities of 300 aldehydes prohibited the Km concentration—of the 4-epimerase substrate, UDP-
Gal. Initial screens identified 39 compounds displayingtype of 1H NMR experiments described above and ne-
cessitated that oxime and hydrazone coupling reactions 30% inhibition or better (Figure 10). We were interested
to observe that while we identified a significant numberbe executed at 0.01 M rather than 0.1 M as performed
previously. To characterize coupling efficiencies under of initial hits, enzyme binding was quite specific; despite
the common uridine scaffold, over 1000 library membersthese conditions, we monitored reaction progress by
reversed-phase HPLC. We quantitated yields after 72 hr inhibited the 4-epimerase by less than 10% (data not
shown). This suggested to us that any 4-epimerase in-by measuring the percent reduction of a peak corre-
sponding to uridine derivative 1, 2, or 3, while observing hibitor identified might possess specific affinity for this
Figure 7. Synthesis of 5-Hydrazide-Phenyl-
sulfonyl-Uridine 3
a, TEA, DMF; b, LiOH, MeOH:H2O (3:1); c, t-BOC-
hydrazide, EDC, HOBt, DMF; d, 40% TFA/
CH2Cl2.
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fore initiating the reaction. (To perform the assay in this
manner for all 1338 compounds in the initial screen was
impractical and unnecessary. The protocol is described
in detail in the Experimental Procedures section.)
Having weeded our results of false positives, we ob-
served no trend favoring library compounds made from
one uridine derivative (1, 2, or 3) over the others. A
solitary compound, designated 1-143, prevailed strik-
ingly; while this compound inhibited 4-epimerase activ-
ity by 78% upon rescreening, no other hits surpassed
35% inhibition. Thus, despite the library’s common uri-
dine scaffold, the 4-epimerase substrate binding pocket
exhibited marked selectivity. As depicted in Figure 11,
potency of compound 1-143 demanded the appropriate
linker between the uridine and aldehyde derivatives;
union of aldehyde 143 with uridine derivative 2 or 3
yielded essentially inactive compounds.
Synthesis and Characterization
of Hit Compound 1-143
To further assess the inhibitory activity of compound
1-143, we resynthesized it on a larger scale (Figure 12).
Theoretically, our product could adopt either the E or Z
configuration about the oxime bond. In our synthesis,
we observed two product isomers distinguishable by
both HPLC and 1H NMR; one was favored overwhelm-
ingly, comprising approximately 90%–95% of the total
product yield. As energetics should favor the E configu-
ration, we predicted that this was our major isomer.
Previous researchers synthesizing an oxime library have
noticed a similar trend (Dustin Maly, personal communi-
cation; [31, 36]). Chemical shifts of the oxime protons
for the two isomers supported this assignment; for the
major isomer, the oxime singlet appeared downfield of
its minor counterpart (8.94 ppm versus 7.90 ppm), which
we and others have observed as characteristic position-Figure 8. Time Courses of Three Library Coupling Reactions, as
ing for E versus Z oxime protons [37, 38].Monitored by 1H NMR
Interestingly, during the course of this synthesis and(A) Coupling reactions observed.
purification, we observed that the two isomers would(B) Reaction progress as assessed by comparing the relative inten-
sity of the aldehyde proton resonance (72A, H depicted in bold) to interconvert in a light-dependent fashion. While the ox-
that of the product oxime or hydrazone proton resonance (16-18, ime-forming reaction favored production of the E iso-
H depicted in bold). mer—as mentioned previously, 90%–95% of the prod-
uct was in this configuration—upon extended exposure
to light the relative ratios of the isomers would reverse,enzyme rather than simple cross-reactivity with any pro-
coming to an equilibrium of approximately 65:35 afterteins that bound uridine.
5 days. This effect was definitively dependent on light;Preliminary inspection of the initial hit structures ap-
1H NMR at temperatures up to 70C detected no alter-peared to favor compounds derived from uridine analog
ations in the isomeric mixture. The interconversion of3 (Figure 10). Of 39 hit compounds, 27 originated with
isomers that we noticed parallels previous reports foranalog 3. This trend withered in follow-up experiments
both alkenes and oximes; UV light may isomerize thein which we rescreened the compounds (Figure 11) or
thermodynamically favored E form to yield the Z isomermeasured their IC50 values. Because our assay em-
[39]. We speculate that the highly conjugated nature ofployed spectrophotometric detection of enzyme activ-
1-143 allows it to undergo this conversion using visibleity, the data could be convoluted by the absorbance or
light. While overall the conversion we observed wassolubility properties of library compounds themselves.
slow, occurring on the order of days, when we purifiedWe observed, for example, that library members derived
the E isomer we found it to be contaminated with a smallfrom compound 3 were more often strongly light absor-
proportion of the Z isomer (for example, 96% E withbent or insoluble in the assay mixture than their counter-
4% Z). Thus, purified material we used in subsequentparts derived from uridine analogs 1 or 2. In our re-
enzymatic assays did contain both isomers; we hypoth-screening protocol, we accounted for such artifacts by
esize, but cannot state definitively, that the E isomerpreincubating the enzyme mixture with the library com-
pound and achieving a stable baseline absorbance be- represents the active form.
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Table 1. Yields for Representative Library Couplings
Values in italics are derived from 1H NMR experiments in which reaction progress was quantitated by comparing the relative intensities of
the aldehyde and oxime or hydrazone proton resonances. All other values were measured by RP-HPLC experiments in which reaction progress
was followed by the disappearance of a peak corresponding to the uridine starting material and the coincident appearance of a product peak.
Asterisks denote reactions in which the presence of side products precluded this method of yield determination.
Inhibitory Activity of Purified 1-143 To evaluate whether the two subunits from which
1-143 was derived—uridine analog 1 and aldehydeagainst the 4-Epimerase
We used the purified 1-143 to define the compound’s 143—themselves inhibited the 4-epimerase, we assayed
each one separately. Assays were performed using 100activity against the 4-epimerase. Because our 4-epi-
merase assay employs an accessory enzyme—the UDP- M UDP-Gal, and up to 2 mM of either 1 or aldehyde 143.
Even at these elevated concentrations, neither subunitGlc dehydrogenase—we were anxious to determine
whether inhibition of that enzyme accounted for the ac- demonstrated appreciable inhibitory activity; the 4-epi-
merase retained 100% activity in the presence of 2 mMtivity we had observed. We performed IC50 measure-
ments for both enzymes, in each case using substrate uridine analog 1 and 72% activity at 2 mM aldehyde
143 (data not shown). Given that the linked compound,concentrations equal to the Km value (4-epimerase,
UDP-Gal, 100M; dehydrogenase, UDP-Glc, 20M). As 1-143, exhibited an IC50 of 25 M, union of the two
subunits rendered a greater than 80-fold enhancementportrayed in Figure 13, compound 1-143 was strikingly
specific for the 4-epimerase; the UDP-Glc dehydroge- of inhibitory capacity. Since neither compound would
have been distinguished if screened separately, thesenase retained its full activity even at 200 M inhibitor,
whereas the 4-epimerase activity was reduced to 10% data demonstrate the utility of our library strategy in
identifying novel bifunctional inhibitors.under analogous conditions.
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fairly specific. To challenge this hypothesis, we assayed
the Streptococcus thermophilus version of the 4-epi-
merase, the porcine UDP-GlcNAc/GalNAc pyrophos-
phorylase, and the bovine (1-4)galactosyltransferase.
We performed IC50 measurements for the three enzymes,
in each case using substrate concentrations equal to
the Km (bacterial 4-epimerase, UDP-Gal, 100 M; pyro-
phosphorylase, UTP, 200 M; galactosyltransferase,
UDP-Gal, 100M). As depicted in Figure 15, 1-143 main-
tained its selective inhibitory behavior. Even at 200 M
1-143, the enzymes retained full activity. The data for the
bacterial 4-epimerase is perhaps especially noteworthy,
as the enzyme is 56% similar to our mammalian target
[44]. One difference in substrate specificity exists be-
tween the two; the bacterial enzyme operates only on
Figure 9. Coupled Enzyme System for the Detection of 4-Epimerase
UDP-Gal and not the N-acetylated sugar. This may sug-Activity
gest that in its interaction with the human enzyme, com-
The assay capitalizes on the 4-epimerase’s ability to catalyze the
pound 1-143 occupies part or all of the pocket normallycarbohydrate C-4 epimerization in either direction; in this case, UDP-
housing the N-acyl group.Gal, used as the substrate, is converted to UDP-Glc by the 4-epi-
merase. UDP-Glc dehydrogenase then oxidizes the product, and
simultaneously reduces two molecules of NAD. The production of
NADH, and hence 4-epimerase activity, is monitored by the change Discussion
in absorbance at 340 nm.
Glycobiology represents an arena in which chemists
can contribute key tools for scientific advance. Because
Finally, to obtain a refined measurement of the com- complex carbohydrate structures are inaccessible to
pound’s potency and to elucidate its mechanism of inhi- direct genetic manipulation—a facile technique for de-
bition, we performed a Ki measurement. Varying concen- riving structural information about proteins—chemical
trations of UDP-Gal (7.8 M–1.0 mM) and 1-143 (10 tools such as enzyme inhibitors may be the most promis-
M–80M) were used to obtain a series of double recip- ing method to modify glycan structures and decode
rocal plots, as displayed in Figure 14. These data dem- structure-function correlations. We have described a
onstrate that 1-143 is a competitive inhibitor versus uridine-derived library directed toward a crucial enzyme
UDP-Gal. The apparent Km of UDP-Gal and Ki of 1-143 in O-linked protein glycosylation—the 4-epimerase; we
were determined to be 140  7 M and 11  0.6 M, hypothesize that further development of the 4-epi-
respectively. These values compare favorably to those merase inhibitor we identified will produce the first
measured for previous, rationally designed substrate O-linked glycosylation inhibitor for use in cultured cells.
analogs of glycosylating enzymes [22–26]. We have In addition, because many glycosylating enzymes act
noted during handling of 1-143 that the compound is upon UDP-linked substrates, we postulate that this uri-
markedly hydrophobic (i.e., it has limited solubility in dine-derived library may serve as a common reservoir
water), suggesting that its membrane permeability may from which one could identify inhibitors of other glycosy-
be superior to previously synthesized, charged sub- lating enzymes. We anticipate that the documented sta-
strate analogs. We look forward to the results of ongoing bility of oxime bonds to physiological pH will imply that
research to test this speculation by monitoring the com- hit compounds generated from this library will prove
pound’s activity in cultured cells. useful in a biological setting [46, 47].
Our screens of the uridine-derived library against the
UDP-GlcNAc 4-epimerase provide useful insights into theInhibitory Activity of 1-143
against Related Enzymes strategy of library design. Previous workers have capital-
ized on the strategy of linking two binding elements toThe abundance of enzymes acting upon UDP-linked
substrates suggests that our uridine-based library could enhance their cumulative potency [31, 36]. In these stud-
ies, monomer elements were initially screened for bindingoffer chemical tools with which to modulate cellular pro-
cesses ranging from nucleotide sugar biosynthesis to by NMR, or for inhibitory activity by an ELISA; monomer
hits were then joined and their combined potency as-glycoprotein and glycolipid elongation, to RNA synthe-
sis [40–43]. These enzymes promised both an array of sessed. The enhancement of potency observed for the
dimer versus the most potent monomer ranged fromfuture targets for our uridine-based library and a signifi-
cant potential risk of unfavorable cross-reactivity with 100- to 625-fold. These values compare favorably with
greater than 80-fold inhibitory enhancement we observedthe 4-epimerase inhibitor we had identified. Thus, as a
forerunner to cultured cell experiments, it was important upon linking aldehyde 143 with uridine derivative 1. Our
approach is distinct in that, since the uridine-derivedto determine if 1-143 showed such unfavorable cross-
reactivity in vitro. We assessed the compound’s selectivity aspect of the library is held constant, the carbohydrate
binding pocket of the enzyme may be targeted specifi-by assaying it against three other enzymes operating
on similar substrates. We had already determined that cally for optimal binders. Thus, structural models of the
interaction of library hits with the enzyme may be pro-1-143 was inactive against the UDP-Glc dehydrogenase,
which suggested to us that its binding interactions were posed, potentially providing a useful topological map of
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Figure 10. Structures of Compounds That Inhibited the 4-Epimerase by 30% or More in Initial Library Screens
The full compound comprises the union of one “R” group depicted below and the indicated uridine derivative above. The bond in bold indicates
the point of attachment. These screens used 100 M of the enzyme substrate, UDP-Gal, and the same concentration of library compound.
The numbers below each R group identify the aldehyde used to make the compound and portray the percent inhibition of enzyme activity
observed in the presence of the library compound. Error indicates high/low between duplicate experiments.
the carbohydrate binding pocket. We hypothesize that that conformational restraints imposed by our current
linkers precluded binding by some aldehyde-derivedthis feature of our library will be more thoroughly ex-
ploited with the incorporation of still more flexible linkers substituents and accounted for the fact that of a 1338
member library, only one compound exhibited greaterthan the ones used in this study. We consider it likely
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Figure 13. Inhibitory Activity of 1-143 against UDP-Glc Dehydroge-
nase and Human 4-Epimerase
For each enzyme, substrate concentrations equal to the Km values
were employed (dehydrogenase (), UDP-Glc, 20 M; 4-epimeraseFigure 11. Inhibitory Activity of Selected Library Compounds
(), UDP-Gal, 100 M). Error bars represent standard deviationagainst the 4-Epimerase
(n  3).Bars represent the activity of compounds generated by the union
of the aldehyde depicted and uridine derivatives 1, 2, or 3. For the
assay, 100 M each of library compound and substrate (UDP-Gal)
Perhaps the most important note about our librarywere used. Error bars indicate standard deviation (n  3). Aldehyde
strategy was its success at generating a 4-epimerasenumbers (in parentheses) correspond with those given in the sup-
inhibitor. With a Ki of 11 M, 13-fold lower than theporting material.
measured Km, compound 1-143 exhibits a binding affin-
ity superior to any neutral inhibitor of a glycosylating
enzyme to date. More potent inhibitors incorporate nu-than 35% inhibition under our screening conditions. In-
deed, in the work cited above, both length and flexibility cleoside phosphates, which are not cell permeable and
therefore of limited utility in cellular assays [26]. Struc-of linkers were found to exert dramatic effects on binding
potency, with constrained analogs of hit compounds tural data may enable second generation enhancement
of this inhibitory activity; the 4-epimerase crystal struc-lagging the activity of their more flexible counterparts
by 9.6- to 28-fold [31, 36]. Current efforts in our lab ture has recently been solved, enabling modeling stud-
ies of the compound’s binding conformation [47]. Fur-explore this facet of library diversification.
Another consequence of our linker choice may have thermore, the compound’s current solubility properties
encourage speculation that the feat of traversing thebeen the marked specificity of the hit compound we
identified for its enzyme target. Of the four additional cell membrane barrier may be possible. Acetylation of
exposed hydroxyl residues could offer means to modu-enzymes tested, none bound 1-143 with measurable
potency. If our linker did constrain conformational mo- late hydrophobicity were it necessary; deacetylation by
cytosolic esterases would be expected to liberate thebility, this could account for the compound’s apparent
inability to achieve profitable interactions with the bind- active compound inside the cell [48].
ing sites of other enzymes. Presumably, too, rigidity
could become an asset if it locks the relevant compound Significance
in a favorable binding orientation. These considerations
are now simple speculations, but in future work the Protein glycosylation represents one of the most per-
vasive and perplexing posttranslational modificationsconsideration of linker flexibility, library binding activity,
and inhibitory potency could be further explored. of proteins. A scarcity of chemical tools particularly
Figure 12. Synthesis of Compound 1-143
Inhibition of the Human GlcNAc 4-Epimerase
123
Figure 14. Lineweaver-Burk Analysis of the
4-Epimerase with Inhibitor 1-143
The concentrations of 1-143 used were 0 M
(H17009), 10 M (), 20 M (), 40 M (), and
80 M (). Dashed lines represent predicted
values based on a competitive inhibition
model.
hampers attempts to understand O-linked glycosyla- chemical tool for controlling O-linked glycosylation;
in addition, the library we describe may serve moretion. This paper describes a strategy to inhibit the
UDP-GlcNAc 4-epimerase, the enzyme responsible for broadly as a reservoir of potential inhibitors for the
many cellular enzymes operating on UDP-linked sub-synthesizing UDP-GalNAc, the carbohydrate donor
needed to initiate O-linked glycosylation. The corner- strates.
stone of our approach was a 1338 member library of
Experimental Proceduresuridine analogs, from which we identified an inhibitor
with a Ki value of 11 M versus the substrate UDP-
General MethodsGal. In vitro tests of the compound’s potency against RP-HPLC was performed on a Rainin Dynamax SD-200 system using
a panel of related enzymes confirmed its specificity Microsorb and Dynamax C18 reversed-phase columns (analytical:
for the 4-epimerase and suggested that testing of the 4.6 mm ID 	 25 cm, 1 ml/min; semipreparative: 10 mm ID 	 25 cm,
4 ml/min) and UV detection (230 nm) was performed with a Rainincompound as an inhibitor of O-linked glycosylation in
Dynamax UV-1 detector. The 1H and 13C NMR spectra were obtainedcultured cells would be warranted. This work repre-
with Bruker AMX-300 and AMX-400 spectrometers. Chemical shiftssents a first step toward developing an important
are reported in parts per million (ppm) (
) downfield from tetrameth-
ylsilane, and coupling constants are reported in Hz. Mass spectrom-
etry (ESI-MS) was performed on a Hewlett-Packard 5989A mass
spectrometer or a Bruker Esquire-LC electrospray ion trap mass
spectrometer.
(t-BOC-aminooxy)acetic acid was purchased from Fluka (15035).
We purchased tert-butyl carbazate (t-BOC hydrazide) from Aldrich
(B9,100-5). Aldehydes 1A-148A were purchased from Aldrich. Alde-
hydes 1-299 were purchased from ChemDiv (San Diego, CA).
Chemical Synthesis
2,3-O-Isopropylidene Uridine (5)
Uridine (4) (5.0 g, 21 mmol) and TsOH (0.6 g, 3.2 mmol) were added
as solids to a flask containing approximately 50 4 A˚ sieves and a
stir bar. DMF (68 ml) was added, and the solids were allowed to
dissolve. 2,2-Dimethoxypropane (10 ml, 82 mmol) was then added
and the mixture heated to 40C. The reaction, monitored by TLC
(CHCl3:MeOH 10:1, UV visualization, product Rf  0.42), was judged
complete in 1.5 hr. At that time, approximately 1 g (10 scoops) of
Amberlyst A-21 ion exchange resin (Aldrich, 21641-0) was added to
neutralize the solution; the mixture was stirred for 25 min and then
filtered through Celite. The product was purified by silica gel chro-
matography, eluting with a gradient of CHCl3:MeOH to yield 5.8 g
(89%) of white solid. 1H NMR (500 MHz, CD3OD) 
 1.36 (s, 3H), 1.56
(s, 3H), 3.73 (dd, 1H, J  4.5, 11.9 Hz), 3.79 (dd, 1H, J  3.6, 11.9
Hz), 4.21–4.23 (m, 1H), 4.83 (dd, 1H, J  3.4, 6.3 Hz), 4.92 (dd, 1H,
J  2.8, 6.3 Hz), 5.70 (d, 1H, J  8.0 Hz), 5.88 (d, 1H, J  2.8 Hz),
Figure 15. Selectivity of Inhibition by 1-143 for the Human 4-Epi- 7.84 (d, 1H, J  8.1 Hz). 13C NMR (100 MHz, CD3OD) 
 25.53, 27.54,
merase 63.05, 82.21, 85.81, 88.37, 94.10, 102.61, 115.10, 143.87, 152.07,
166.21. Analytical calculated for C12H16N2O6: C, 50.70; H, 5.67; N,Inhibitory activity of 1-143 against UDP-GlcNAc/GalNAc pyrophos-
phorylase (), bacterial 4-epimerase (), (1-4)galactosyltransfer- 9.85. Found: C, 50.42; H, 5.79; N, 9.79.
2,3-O-Isopropylidene-5-O-Toluenesulfonyluridine (6)ase (), and human 4-epimerase (). For each enzyme, substrate
concentrations equal to the Km values were employed (bacterial 2,3-O-Isopropylidene uridine (5) (4.1 g, 14 mmol) was suspended
in CH2Cl2 (58 ml); the subsequent addition of pyridine (11.7 ml, 1444-epimerase, UDP-Gal, 100 M; pyrophosphorylase, UTP, 200 M;
galactosyltransferase, UDP-Gal, 100M; human 4-epimerase, UDP- mmol) caused compound 5 to dissolve completely. After addition
of Ts2O (7.5 g, 23 mmol), the solution turned yellow and warmedGal, 100 M). Error bars represent standard deviation (n  3).
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slightly. The reaction was heated at reflux for 2 hr, at which point heated at 45C overnight; as monitored by TLC (hexanes:ethyl ace-
tate, 1:1.5, UV visualization), it was judged complete the followingit was judged complete by TLC (CHCl3:MeOH, 10:1, UV visualization).
The reaction was diluted with 250 ml of CHCl3 and washed with 0.5 morning. Because the azido-uridine product (9) was unreactive to
all reduction conditions tested, including Staudinger conditions, itM HCl (5 	 100 ml) and saturated NaHCO3 (2 	 100 ml). After drying
over Na2SO4, the organic layer was filtered, concentrated in vacuo, was fruitless to attempt to monitor the reaction using triphenylphos-
phine/ninhydrin staining. The solution was concentrated in vacuoand coevaporated with toluene until the crude product was a yellow
solid. Purification by silica gel chromatography eluting with a gradi- and coevaporated with toluene several times to remove residual
DMF. Because the product partitioned between aqueous and or-ent of CHCl3:MeOH yielded 6.2 g (98%) of an off-white solid. 1H NMR
(500 MHz, CDCl3) 
 1.30 (s, 3H), 1.51 (s, 3H), 2.40 (s, 3H), 4.22–4.28 ganic layers, the crude mixture was purified directly by silica gel
chromatography using a gradient of CHCl3:MeOH to yield 4.4 g (98%)(m, 2H), 4.30-4.33 (m, 1H), 4.77 (dd, 1H, J  3.8, 6.4 Hz), 4.94 (dd,
1H, J  1.9, 6.4 Hz), 5.62 (d, 1H, J  1.9 Hz), 5.70 (app d, 1H, J  of a hygroscopic off-white solid. 1H NMR (500 MHz, CDCl3) 
 1.32
(s, 3H), 1.53 (s, 3H), 3.59–3.61 (m, 2H), 4.19–4.21 (m, 1H), 4.80 (dd,8.0 Hz), 7.24 (d, 1H, J  8.1 Hz), 7.30 (d, 2H, J  8.0 Hz), 7.73 (d,
2H, J  8.3 Hz), 9.96 (app s, 1H). 13C NMR (100 MHz, CDCl3) 
 1H, J  4.2, 6.5 Hz), 4.99 (dd, 1H, J  2.1, 6.5 Hz), 5.64 (d, 1H, J 
2.1 Hz), 5.74 (d, 1H, J  8.0 Hz), 7.30 (d, 1H, J  8.1 Hz), 10.18 (s,21.72, 25.22, 27.06, 69.53, 80.92, 84.40, 85.24, 95.04, 102.71, 114.66,
128.02, 129.95, 132.52, 142.67, 145.34, 150.20, 163.79. 1H). 13C NMR (500 MHz, CDCl3) 
 25.26, 27.12, 52.38, 81.60, 84.36,
85.96, 94.91, 102.86, 114.78, 142.75, 150.30, 163.91.2,3-O-Isopropylidene-5-O-Succinimidyluridine (7)
2,3-O-Isopropylidene-5-O-toluenesulfonyluridine (6) (7.0 g, 16 5-Azido-5-Deoxy Uridine (10)
To a flask containing 5-azido-5-deoxy-2,3-O-isopropylidene uri-mmol) and N-hydroxysuccinimide (5.5 g, 48 mmol) were dissolved
in DMF (40 ml); DIEA (14 ml, 80 mmol) was added, and the solution dine (9) (3.2 g, 10 mmol), 60 ml of 90% TFA in water was added.
The reaction, monitored by TLC (CHCl3:MeOH, 6:1, UV visualization),was stirred at 40C for 6 hr. At this time, the reaction was judged
complete by TLC (CHCl3:MeOH, 6:1, UV visualization). The solution, was complete within 20 min. At that time, the solution was concen-
trated in vacuo, with repeated coevaporation with toluene to removeconcentrated in vacuo, was coevaporated with toluene to ensure
removal of the DMF. The crude mixture was dissolved in 600 ml of residual water. The product was purified by silica gel chromatogra-
phy eluting with a gradient of CHCl3:MeOH to yield 2.7 g (96%) ofCHCl3 and washed with 0.5 M HCl (3	 100 ml) and saturated NaHCO3
(1 	 100 ml). Numerous back-extractions of the aqueous layers a white glass. 1H NMR (500 MHz, CD3OD) 
 3.60 (dd, 1H, J  4.8,
13.4 Hz), 3.69 (dd, 1H, J 3.2, 13.4 Hz), 4.04–4.08 (m, 1H), 4.09–4.11were required to rescue the product. The combined organic layers
were dried over Na2SO4, filtered, and concentrated in vacuo. Purifi- (m, 1H), 4.21–4.23 (m, 1H), 5.74 (d, 1H, J  8.1 Hz), 5.84 (d, 1H, J 
4.3 Hz), 7.72 (d, 1H, J  8.1 Hz). 13C NMR (500 MHz, CD3OD) 
 53.05,cation was accomplished by silica gel chromatography eluting with
a gradient of CHCl3:MeOH to yield 4.6 g (76%) of an off-white solid. 71.70, 74.79, 83.73, 91.72, 103.01, 142.63, 152.25, 166.07. Analytical
calculated for C9H11N5O5: C, 40.15; H, 4.12; N, 26.01. Found: C, 40.12;1H NMR (500 MHz, CD3OD) 
 1.36 (s, 3H), 1.55 (s, 3H), 2.68 (s, 4H),
4.33 (d, 2H, J  4.4 Hz), 4.45–4.48 (m, 1H), 4.97 (dd, 1H, J  2.4, H, 4.37; N, 25.90.
5-Amino-5-Deoxy Uridine (11)6.3 Hz), 4.99 (dd, 1H, J  3.0, 6.3 Hz), 5.69 (d, 1H, J  8.0 Hz), 5.84
(d, 1H, J  2.4 Hz), 7.84 (d, 1H, J  8.1 Hz). 13C NMR (100 MHz, 5-Azido-5-deoxy uridine (10) (2.5 g, 9.3 mmol) was suspended in
MeOH (60 ml) and 10% Pd/C (0.5 g) was added. While the mixtureCD3OD) 
 25.52, 26.47, 27.46, 77.52, 82.42, 85.64, 85.99, 95.11,
102.82, 115.27, 144.20, 152.00, 166.14, 173.68. HRMS calculated for was stirred at room temperature, H2 gas was bubbled through the
solvent; the starting material gradually dissolved as the reactionC16H20N3O8 (M  H), 382.1250; found, 382.1240.
5-O-Succinimidyluridine (8) progressed. As monitored by TLC (CHCl3:MeOH, 2:1, UV and ninhy-
drin visualization), the reaction was complete in 3 hr. The solution,2,3-O-Isopropylidene-5-O-succinimidyluridine (7) (3.6 g, 9.4
mmol) was dissolved in 50 ml of 90% TFA in H2O. The reaction, filtered through Celite, was concentrated in vacuo to yield 2.2 g
(98%) of product judged sufficiently clean by 1H NMR to carry onmonitored by TLC (CHCl3:MeOH, 10:1, UV visualization) was com-
plete within 25 min. The solution was concentrated in vacuo, with without further purification. 1H NMR (500 MHz, d6-DMSO) 
 2.74 (dd,
1H, J  5.4, 13.6 Hz), 2.79 (dd, 1H, J  4.5, 13.6 Hz), 3.74-3.76 (m,subsequent coevaporation with toluene to remove residual solvent.
Purification by silica gel chromatography, eluting with a gradient of 1H), 3.91 (m, 1H), 4.06 (app t, 1H, J  5.5 Hz), 5.63 (d, 1H, J  8.0
Hz), 5.74 (d, 1H, J  5.6 Hz), 7.85 (d, 1H, J  8.1 Hz). 13C NMR (500CHCl3:MeOH, yielded 3.1 g (97%) of a hygroscopic white solid. 1H
NMR (500 MHz, d6-DMSO) 
 2.61 (s, 4H), 4.03–4.09 (m, 3H), 4.18 MHz, d6-DMSO) 
 43.16, 70.40, 73.02, 85.01, 88.07, 101.95, 141.43,
150.85, 163.22. HRMS calculated for C9H14N3O5 (M  H), 244.0933;(dd, 1H, J  2.6, 10.6 Hz), 4.25 (dd, 1H, J  4.9, 10.6 Hz), 5.33 (d,
1H, J  4.3 Hz), 5.50 (d, 1H, J  5.1 Hz), 5.61 (dd, 1H, J  2.2, 8.1 found, 244.0939.
Compound 12Hz), 5.78 (d, 1H, J  5.0 Hz), 7.78 (d, 1H, J  8.1 Hz), 11.36 (d, 1H,
J  1.9 Hz). 13C NMR (500 MHz, d6-DMSO) 
 25.47, 69.96, 72.87, 5-Amino-5-deoxy uridine (11) (2.0 g, 8.2 mmol), HOBt (1.9 g, 12
mmol), and (t-BOC-aminooxy)acetic acid (3.1 g, 16 mmol) were dis-76.23, 81.52, 88.25, 101.98, 140.91, 150.70, 163.05, 171.91. Analyti-
cal calculated for C13H15N3O8  H2O: C, 43.46; H, 4.77; N, 11.70. solved together in DMF (33 ml) and stirred at room temperature for
30 min. EDC (2.4 g, 12 mmol) was then added. The mixture wasFound: C, 43.32; H, 4.68; N, 11.57.
5-Aminooxyuridine (1) stirred at room temperature under Ar for approximately 14 hr, at
which time the reaction appeared complete by TLC (CHCl3:MeOH,5-O-Succinimidyluridine (8) (3.0 g, 8.8 mmol) was dissolved in a 2:1
mixture of 40% MeNH2/H2O and MeOH (60 ml total) and heated to 2:1, UV visualization). The solution was concentrated in vacuo, with
repeated coevaporation with toluene to remove residual DMF. Thereflux. As monitored by TLC (CHCl3:MeOH, 2:1, UV visualization), the
reaction was complete within 2 hr. The solution was concentrated in crude product was purified by silica gel chromatography eluting
with a gradient of CHCl3:MeOH to yield 3.1 g (91%) of an off-whitevacuo to provide an off-white solid, which was redissolved in H2O
with trace CH3CN added to aid dissolution. The product was purified solid. 1H NMR (500 MHz, d6-DMSO) 
 1.39 (s, 9H), 3.29–3.34 (m, 1H),
3.47–3.52 (m, 1H), 3.81–3.88 (m, 2H), 4.06 (app q, 1H, J  5.5 Hz),by HPLC on a preparative aminopropyl silica gel column (Rainin,
21.4 mm diameter, 25 cm length, 60 A˚ pore) eluting with a gradient 4.18 (s, 2H), 5.19 (d, 1H, J  5.2 Hz), 5.40 (d, 1H, J  5.7 Hz), 5.63
(dd, 1H, J  2.2, 8.1 Hz), 5.73 (d, 1H, J  5.6 Hz), 7.66 (d, 1H, J of CH3CN:H2O (100% to 50% CH3CN over 45 min). Lyophilization
yielded 2.3 g (59%) of a fluffy white solid. 1H NMR (500 MHz, 8.1 Hz), 8.17 (app s, 1H), 10.28 (s, 1H), 11.35 (d, 1H, J  2.0 Hz). 13C
NMR (500 MHz, d6-DMSO) 
 27.93, 40.61, 70.81, 72.51, 74.73, 80.72,d6-DMSO) 
 3.68 (dd, 1H, J  5.1, 11.2 Hz), 3.74 (dd, 1H, J  3.4,
11.2 Hz), 3.91–3.92 (m, 1H), 3.95–3.97 (m, 1H), 4.02 (app dd, 1H, J  82.26, 88.30, 102.00, 141.22, 150.73, 156.92, 163.07, 168.29. Analyti-
cal calculated for C16H24N4O9  H2O: C, 44.24; H, 6.03; N, 12.90.5.2, 10.5 Hz), 5.21 (d, 1H, J  4.5 Hz), 5.42 (d, 1H, J  5.6 Hz), 5.65
(dd, 1H, J  0.2, 8.1 Hz), 5.75 (d, 1H, J  5.5 Hz), 6.18 (s, 2H), 7.68 Found: C, 44.09; H, 5.89; N, 12.93.
Compound 2(d, 1H, J  8.1 Hz), 11.33 (s, 1H). 13C NMR (500 MHz, d6-DMSO) 

70.26, 72.99, 75.40, 82.16, 88.08, 102.06, 140.89, 150.76, 163.14. Compound 12 (3.4 g, 8.2 mmol) was dissolved in a solution of 40%
TFA in CH2Cl2 (150 ml). The presence of TFA complicated the moni-HRMS calculated for C9H13N3O6 (MH), 260.0883; found, 260.0884.
5-Azido-5-Deoxy-2,3-O-Isopropylidene Uridine (9) toring of the reaction by TLC (CHCl3:MeOH, 2:1, UV visualization), but
the reaction progress was rapid and deprotection was definitively2,3-O-Isopropylidene-5-O-toluenesulfonyluridine (3.20) (6.0 g, 14
mmol) was dissolved in DMF (34 ml). LiN3 (3.4 g, 68 mmol) [49] was complete within 45 min. The reaction was stopped by concentration
in vacuo; coevaporation with toluene ensured removal of the TFA.added; this compound never entirely dissolved. The reaction was
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The crude product was purified by HPLC on a preparative aminopro- HOBt often coeluted with the product during purification; most often
the product was carried forward without further separating this mi-pyl silica gel column (Rainin, 21.4 mm diameter, 25 cm length, 60 A˚
pore) eluting with a gradient of CH3CN:H2O. Lyophilization yielded nor impurity. 1H NMR (500 MHz, MeOD) 
 3.16 (dd, 1H, J  5.7,
14.1 Hz), 3.24–3.31 (m, 2H), 3.91–3.94 (m, 1H), 4.07 (app t, 1H, J 1.2 g (45%) of a fluffy white solid. 1H NMR (500 MHz, d6-DMSO) 

3.29–3.34 (m, 1H), 3.42–3.47 (m, 1H), 3.84–3.87 (m, 1H), 3.90–3.92 5.5 Hz), 4.19–4.22 (m, 1H), 5.70 (d, 1H, J  8.0 Hz), 5.73 (d, 1H, J 
4.8 Hz), 7.65 (d, 1H, J  8.1 Hz), 7.95 (d, 2H, J  8.4 Hz), 8.00 (d,(m, 1H), 3.97 (s, 1H), 4.07 (app t, 1H, J  5.5 Hz), 5.19 (s, 1H), 5.39
(s, 1H), 5.64 (d, 1H, J  8.0 Hz), 5.72 (d, 1H, J  5.7 Hz), 6.34 (s, 2H, J  8.2 Hz). 13C NMR (500 MHz, MeOD) 
 28.45, 28.55, 44.91,
45.56, 71.86, 74.47, 82.08, 83.87, 91.92, 102.94, 128.19, 129.46,2H), 7.67 (d, 1H, J  8.1 Hz), 7.94 (app t, 1H, J  6.0 Hz), 11.28 (s,
1H). 13C NMR (500 MHz, d6-DMSO) 
 40.53, 70.92, 72.57, 74.41, 143.18, 144.98, 152.35, 166.18, 168.23. HRMS calculated for
C21H27N5O10S1 (M  H), 542.1557, found 542.1554.82.57, 88.44, 102.10, 141.50, 150.88, 163.27, 170.38. Analytical cal-
culated for C11H16N4O7: C, 41.77; H, 5.10; N, 17.72. Found: C, 41.33; Compound 3
Compound 15 (2.1 g, 3.9 mmol) was dissolved in a solution of 40%H, 5.32; N, 17.40.
4-Chlorosulfonyl Benzoic Acid Methyl Ester (13) TFA in CH2Cl2 (60 ml). Bubbles of CO2 were observed upon addition
of solvent. The reaction was stirred at room temperature for 2 hr,4-Chlorosulfonyl benzoic acid (5.0 g, 23 mmol) was suspended in
a mixture of thionyl chloride (20 ml) and dichloroethane (10 ml), the at which time it appeared to be complete by TLC analysis
latter added to enhance the solubility of the starting material. The (CHCl3:MeOH, 2:1, UV visualization). The reaction was concentrated
mixture was heated to reflux; gradually, the starting material dis- in vacuo, with subsequent rounds of coevaporation with toluene to
solved during heating. The reaction was heated at reflux for 1 hr ensure removal of the TFA. The crude product, an off-white glass,
following complete dissolution of the starting material, at which time was dissolved in MeOH and purified by HPLC on a preparative
it was concentrated in vacuo to a light-brown solid, presumably the aminopropyl silica gel column (Rainin, 21.4 mm diameter, 25 cm
crude intermediate 4-chlorosulfonyl benzoyl chloride. This material length, 60 A˚ pore), eluting with a gradient of CH3CN:H2O (100% to
was chilled on ice for several minutes; ice-cold MeOH (40 ml) was 50% CH3CN over 45 min). Lyophilization yielded 0.94 g (55%) of a
then added and the mixture stirred on ice for 5 min, which left most fluffy white solid. 1H NMR (500 MHz, d6-DMSO) 
 2.95 (dd, 1H, J 
but not all of the solid dissolved. The reaction was then removed 6.5, 13.8 Hz), 3.09 (dd, 1H, J  4.9, 13.7 Hz), 3.76–3.79 (m, 1H),
from ice and stirred at room temperature for 10 min, during which 3.87–3.89 (m, 1H), 4.06 (app t, 1H, J  5.5), 4.58 (s, 2H), 5.25 (s, 1H),
time a white precipitate was formed. Addition of ice-cold H2O (40 5.45 (s, 1H), 5.61 (d, 1H, J  8.1 Hz), 5.71 (d, 1H, J  6.0 Hz), 7.64
ml) yielded copious precipitation. The solid product was filtered (d, 1H, J  8.1 Hz), 7.86 (app d, 2H, J  8.7 Hz), 7.98 (app d, 2H,
from the solvent, washed with additional ice-cold H2O, and dried J  8.7 Hz), 10.01 (s, 1H). 13C NMR (500 MHz, d6-DMSO) 
 44.65,
under vacuum to yield 4.6 g (86%) of white solid judged 95% pure 70.47, 72.13, 82.56, 88.15, 101.96, 126.55, 127.90, 136.80, 141.42,
by 1H NMR [50]. 1H NMR (500 MHz, CDCl3) 
 3.97 (s, 3H), 8.24 (d, 142.65, 150.76, 157.89, 158.14, 163.07, 164.59. HRMS calculated for
2H, J  2.0 Hz), 8.26 (d, 2H, J  1.9 Hz). 13C NMR (500 MHz, CDCl3) C16H20N5O8S1 (M  H), 442.1033; found 442.1026.

 52.91, 127.00, 130.79, 136.01, 147.33, 164.83. Compound 1-143
Compound 14 Aldehyde 143 (15 mg, 0.060 mmol) and uridine derivative 1 (20 mg,
5-Amino-5-deoxy uridine (11) (2.0 g, 8.2 mmol) was dissolved in 0.077 mmol) were combined in 1% AcOH/DMSO (600 l), vortexed,
DMF (33 ml). TEA (2.3 ml, 16 mmol) and 4-chlorosulfonyl benzoic and incubated at room temperature in the dark overnight. The reac-
acid methyl ester (13) (2.3 g, 9.8 mmol) were added, yielding a pale tion, as monitored by RP-HPLC, was complete the next day. Com-
yellow mixture in which some undissolved sulfonyl chloride was pound 1-143 was purified by RP-HPLC using a gradient of CH3CN/
suspended. The reaction was stirred at room temperature overnight. NH4OAc (25 mM, pH 7.0); lyophilization yielded 19 mg (65%) of
As monitored by TLC (CHCl3:MeOH, 2:1, UV visualization), the reac- product. As described in the text, the E isomer was invariably mixed
tion was judged complete the following morning. The coupled prod- with a small percentage of Z isomer. For the assays described
uct was insoluble in most solvents and was most efficiently purified herein, that mixture—as estimated by 1H NMR analysis of oxime
by precipitation from MeOH in three successive batches, which proton resonances—was 96% E (oxime resonance at 8.94 ppm) to
yielded 2.5 g (70%) of white solid judged 95% pure by 1H NMR. 4% Z (oxime resonance at 7.90 ppm). 1H NMR of E isomer (500 MHz,
1H NMR (500 MHz, d6-DMSO) 
 2.97–3.02 (m, 1H), 3.11–3.15 (m, 1H), d6-DMSO): 
 4.05-4.06 (m, 1H), 4.10-4.14 (m, 2H), 4.40 (dd, 1H, J 
3.74–3.77 (m, 1H), 3.85–3.88 (m, 1H), 3.89 (s, 3H), 4.04 (app q, 1H, 5.5, 12.2 Hz), 4.47 (dd, 1H, J  3.5, 12.3 Hz), 5.30 (app s, 1H), 5.49
J  5.7 Hz), 5.20 (d, 1H, J  5.3 Hz), 5.40 (d, 1H, J  5.8 Hz), 5.60 (d, 1H, J  5.5 Hz), 5.56 (d, 1H, J  8.1 Hz), 5.80 (d, 1H, J  5.1
(dd, 1H, J  1.9, 8.0 Hz), 5.68 (d, 1H, J  5.9 Hz), 7.61 (d, 1H, J  Hz), 7.26 (d, 1H, J  9.0 Hz), 7.62 (dd, 1H, J  2.2, 9.2 Hz), 7.72 (d,
8.1 Hz), 7.92–7.95 (m, 2H), 8.11–8.15 (m, 2H), 11.34 (d, 1H, J  1.6 1H, J  8.1 Hz), 7.88 (d, 1H, J  9.0 Hz), 8.13 (d, 1H, J  2.1 Hz),
Hz). 13C NMR (500 MHz, d6-DMSO) 
 44.66, 52.64, 70.43, 72.10, 82.41, 8.65 (d, 1H, J  9.2 Hz), 8.94 (s, 1H), 11.34 (s, 1H). 13C NMR (500
88.18, 101.95, 126.93, 130.02, 132.86, 141.39, 144.65, 150.71, 163.01, MHz, d6-DMSO): 
 69.89, 72.70, 73.87, 82.17, 88.45, 101.87, 108.72,
165.21. HRMS calculated for C17H20N3O9S1 (M  H), 442.0920; 116.19, 119.35, 126.59, 129.47, 129.80, 130.27, 130.38, 131.62,
found, 442.0920. 140.80, 147.11, 150.65, 156.66, 162.99. HRMS calculated for
Compound 15 C20H20Br1N3O7 (M  H), 494.0386; found, 494.0383.Compound 14 (1.6 g, 3.6 mmol) was suspended in a 3:1 mixture of
MeOH:H2O (36 ml total) and stirred on ice for 15 min. LiOH (0.43 g,
Library Coupling Reactions18 mmol) was added, causing the uridine derivative to dissolve; the
For aldehydes 1A-148A, since quantities permitted, the aldehydessolution was stirred on ice overnight. The following morning, the
were dissolved in DMSO at a concentration of 0.2 M. These solutionsreaction was judged complete by TLC analysis (CHCl3:MeOH 2:1,
were incubated at room temperature for 3 days to maximize dissolu-UV visualization). Approximately 1 g of Amberlite IRC-50 resin was
tion of the aldehydes. Some compounds never fully dissolved (38A,added to neutralize the basic solution, and the mixture was stirred
43A, 101A, 106A, 107A, 109A, 110A, 112A); in these cases, theat room temperature for 30 min. The solution was removed from
suspension was used for the coupling reaction, and it should bethe resin by filtration and the solution concentrated in vacuo; the
assumed that the concentrations of these aldehydes have beencrude product was taken on without purification to the next reaction.
overestimated. Aldehyde 113A was not used for library couplings,This intermediate was dissolved in anhydrous DMF (18 ml), which
as it was too volatile to handle accurately. Uridine derivatives 1, 2,was followed by the successive additions of HOBt (0.83 g, 5.4 mmol)
and 3 were dissolved in 2% AcOH/DMSO (vol/vol) at a concentrationand t-BOC hydrazide (0.95 g, 7.2 mmol). The resultant solution was
of 0.22 M. Equal volumes (50 L each) of aldehyde and uridinestirred at room temperature under Ar for 15 min. EDC (1.0 g, 5.4
derivative were combined, vortexed, and incubated at room temper-mmol) was then added and the reaction stirred at room temperature
ature in the dark for 4 days. At this point, the couplings were as-under Ar overnight. The following morning, the reaction was judged
sumed to be complete, and the library solutions were stored atcomplete by TLC analysis (CHCl3:MeOH, 2:1, UV visualization); con-
–20C. Aliquots of these 100 mM solutions were diluted 50-fold withcentration in vacuo, followed by coevaporation with toluene, was
DMSO, to a final concentration of 2 mM, for use in library screening.performed to remove all solvent. Purification was accomplished by
The efficiencies of 33 of these library couplings (the reactions ofsilica gel chromatography using a gradient of CHCl3:MeOH to yield
1.9 g (97% over two steps) of white solid. It should be noted that uridine derivatives 1, 2, and 3 with 11 aldehydes each, as depicted
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in Table 1) were quantitated by 1H NMR. Identical conditions to those bition was calculated using the following formula: % inhibition 
100  ((experimental rate/control rate)*100). The control rate repre-just described were used, except that d6-DMSO was substituted as
the solvent, and a suitable volume was employed to allow 1H NMR sented the average of quadruplicate samples containing 5 L of
DMSO in place of 5 L of library compound dissolved in DMSO.readings. The product yield was calculated by comparing the rela-
tive intensities of the product oxime or hydrazone proton resonance For initial library screening, the compounds were screened in dupli-
cate and error depicted by high/low values.(typically found between 7.0 and 9.5 ppm) with that of the starting
material aldehyde proton resonance (typically found between 8.5 Because this assay monitors light absorption, results were in
some cases complicated by the spectrophotometric properties ofand 11.0 ppm). The identities of the coupled products were con-
firmed by electrospray mass spectrometry. the library compounds themselves. Specifically, we observed that
the absorbance of the library compounds sometimes changed uponAldehydes 1-299 were purchased as 20 mM solutions in DMSO.
In some cases, the compounds were not fully soluble at this concen- incubation with enzyme cocktail, irrespective of the presence of the
enzyme substrate, UDP-Gal. This led to the identification of falsetration; if so, the suspension was used. Uridine derivatives 1, 2, and
3 were dissolved in 0.2% AcOH/DMSO (vol/vol) at a concentration positives in the initial screens. To clarify the activity of the library
compounds, the assay protocol was altered slightly in rescreeningof 22 mM. Equal volumes (25 L each) of aldehyde and uridine
derivative were combined, vortexed, and incubated at room temper- and IC50 experiments. All reagents were used in the final concentra-
tions described above. In the revised format, only 5 L of libraryature in the dark for 4 days. At this point, the couplings were as-
sumed to be complete, and the library solutions stored at –20C. compound, and no UDP-Gal, was aliquoted into the microplate. The
remaining reagents were divided into two cocktails, both assembledAliquots of these 10 mM solutions were diluted 5-fold with DMSO,
to a final concentration of 2 mM, for use in library screening. on ice: (A) contained 4-epimerase, UDP-Glc dehydrogenase, -NAD,
and potassium bicinate; and (B) contained UDP-Gal, -NAD, andThe efficiencies of 99 of these library couplings (the reactions of
uridine derivatives 1, 2, and 3 with 33 aldehydes each, as depicted potassium bicinate. Cocktail A was incubated at room temperature
for 5 min prior to assay initiation, and then 45 L per well wasin Table 1) were quantitated by RP-HPLC. A gradient of CH3CN/
NH4OAc (25 mM, pH 7.0) (10%–80% NH4OAc over 8 min) was used dispensed with a multichannel pipettor. Absorbance at 340 nm was
monitored for 5–10 min, until those readings achieved a stable base-on an analytical C18 column (Rainin, 4.6 mm diameter, 25 cm length,
100 A˚ pore); absorbance was monitored at 254 nm. Standard curves line. Cocktail B, which was incubated at room temperature for 10
min prior to use, was then dispensed at 50 L per well; this initiatedof each uridine derivative were measured to correlate the ab-
sorbance intensity with the concentration of uridine analog. To cal- the enzymatic reaction. As previously, absorbance at 340 nm was
monitored for 5 min, and initial rates were calculated and comparedculate library coupling yields, we exposed an aliquot of the reaction
mixture to the same RP-HPLC conditions, and the intensity of the to a control exposed to only DMSO.
Ki Measurementpeak corresponding to the uridine analog was compared to the
standard curves generated previously. The percent diminution of UDP-Gal was aliquoted to a 96-well plate (10 L per well of 10	
stock solutions designed to yield final concentrations ranging fromthe uridine starting material was assumed to represent a coincident
percent accumulation of product. This method of yield estimation 7.6 	 106 M to 1.0 	 103 M). A suitable amount of compound
1-143 was added to five separate batches of enzyme cocktail sodemanded the presence of a solitary product; in those cases where
multiple product peaks were observed, this method was judged as to yield final concentrations in the wells of 0, 10, 20, 40, and 80 	
106 M 1-143. The enzyme/1-143 cocktail was incubated at roominappropriate to estimate yields. The identities of the coupled prod-
ucts were confirmed by electrospray mass spectrometry. temperature for 10 min prior to the reaction. Reactions were initiated
by the addition of the enzyme/1-143 cocktail to the UDP-Gal-con-
taining wells (90L of cocktail per well). Each concentration of UDP-Spectrophotometric Assay for 4-Epimerase Activity
General Conditions Gal/1-143 was measured in duplicate. Initial rates were calculated as
described previously. The data were fit by nonlinear regression analysisActivity of the 4-epimerase was monitored using a coupled enzyme
assay as summarized below: to a competitive inhibition model using SAS software (Cary, NC).
UDP-Gal (4-epimerase)→ UDP-Glc
Purification of Human 4-EpimeraseUDP-Glc  2 NAD (UDP-Glc dehydrogenase)→ UDP-Glucuronic
The yeast strain JFY1023, which expresses the human 4-epimeraseacid  2 NADH
with a C-terminal His6 tag, was prepared previously by Fridovich-
Keil and coworkers and was a generous gift to us from that lab.The production of NADH, and hence the activity of the 4-epimerase,
was monitored by measuring the absorbance at 340 nm. Assays Protocols for protein expression and purification are derived from
those described previously [51, 52]. Cultures of JFY1023 yeast (4 	were performed in half-area 96-well plates (Corning costar 3696)
with 100 L per well unless reagents were limiting, in which case 1 liter) were grown at 30C in minimal complete dextrose medium
deficient in histidine (SD-His, Clontech 8602-1, 8606-1) to an OD(60050 l per well was used. Protocols that follow assume 100 L per
well. For library screening, each well contained assay reagents in nm)  0.6–0.8. Yeast cells were pelleted by centrifugation (1000 	
g, 5 min, 4C) and either stored frozen at80C or used immediately.the following final concentrations: 100 M library compound; 100
M UDP-Gal (Calbiochem 670111); 0.1 mU bacterial 4-epimerase The following “purification buffer” was common to all subsequent
steps: 20 mM HEPES (pH 7.5) (Sigma H0763), 200 mM NaCl, 4 mM(Calbiochem 670112) or 0.05 mU human 4-epimerase (purification
from yeast described below; note that less human enzyme was -NAD (Sigma N1511), and 1	 protease inhibitors. -NAD was
included to stabilize the 4-epimerase. Protease inhibitors wereused simply to conserve enzyme); 16 mU UDP-Glc dehydrogenase
(Calbiochem 670121); 1.25 mM -NAD (Sigma N1511); 125 mM stored as a 100	 cocktail in DMSO and dispensed into the buffer
immediately prior to use. The following compounds were included inpotassium bicinate (pH 8.5) (Sigma B3876).
Library Screening the 100	 cocktail: pepstatin A (Sigma P5318) at 100g/ml, aprotinin
(Sigma A1153) at 210 g/ml, leupeptin (Sigma L2884) at 50 g/For library screening, 5 L of each of library compound or control
(0.02% AcOH/DMSO solution) and UDP-Gal (H2O solution) were ali- ml, antipain (Sigma A6191) at 260 g/ml, phosphoramidon [N-(-
rhamnopyranosyloxyhydroxy-phosphinyl)-leu-trp, Sigma R7385] at 60quoted to each well. An enzyme cocktail comprising appropriate
concentrations of the remaining reagents was assembled on ice; g/ml, E64 [trans-epoxysuccinyl-L-leucylamido(4-guanidino)-
butane, Sigma 3132] at 750 g/ml, and chymostatin (Sigma C7268)this cocktail was incubated at room temperature for 10 min prior to
assay initiation to allow its temperature to equilibrate. The assay at 10 g/ml. A separate 100	 solution of Pefabloc SC (Boehringer
Mannheim 1429 868) at 24 mg/ml in DMSO was used as well. Allwas initiated by dispensing 90 L of cocktail per well using a multi-
channel pipettor. Absorbance at 340 nm was monitored on a Molec- steps of the purification protocol were performed either on ice or
at 4C, using prechilled buffers, to stabilize the 4-epimerase andular Devices SpectraMAX190 microplate reader for 5 min, with read-
ings every 3 s. Note that to achieve readings of this frequency, only minimize protease activity.
For preparation of the yeast extract, the yeast pellet was sus-three columns of the plate could be read at once. Initial rates of
enzymatic reactions were determined using the SoftMAX Pro soft- pended in a minimum (5–10 ml) of purification buffer containing 25
mM imidazole at pH 7.5. The suspension was transferred to a 30ware that accompanies the SpectraMAX190 machine. Percent inhi-
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ml BioSpec Bead Beater bottle that had been half-filled with 0.5 Spectrophotometric Assay for UDP-GlcNAc/GalNAc
Pyrophosphorylase Activitymm glass beads (BioSpec 11079105). Additional purification buffer
with 25 mM imidazole was used to rinse residual yeast into the The UDP-HexNAc pyrophosphorylase, a porcine version of the en-
zyme expressed with a His6 tag in E. coli, was a generous gift frombottle and to fill it to within 0.5 cm of its top. The Bead Beater was
assembled, with crushed dry ice surrounding the bottle to keep its Dr. Alan Elbein [53]. Activity of the UDP-HexNAc pyrophosphorylase
was monitored as described by the equation below. Note that whilecontents chilled. The Bead Beater was pulsed on for 2 min, then
off for 30 s, for a total of six cycles; the 30 s intervals between the preferred substrates for this enzyme are the N-acetamido
sugars—either GlcNAc-1-phosphate or GalNAc-1-phosphate—pulses were designed to allow the bottle’s contents to cool after
they were warmed by beating. The yeast extract was separated glucose-1-phosphate (Glc-1-P) is accepted as an alternative sub-
strate, making possible the spectrophotometric assay describedfrom the glass beads by filtration through glass wool in a 60 ml
plastic syringe; additional purification buffer with 25 mM imidazole here.
was used to rinse the bottle and beads. The extract was centrifuged
Glc-1-P  UTP (UDP-HexNAc pyrophosphorylase)→ UDP-Glc at 4C (15000 	 g, 15 min) to pellet cellular debris. If the resultant
pyrophosphate (PPI)lysate was still opaque, centrifugation was repeated for 5 min.
UDP-Glc  2 NAD (UDP-Glc dehydrogenase) →Purification of the His6-tagged 4-epimerase from the crude cell
UDP-GlcA  2 NADHlysate was accomplished by loading the approximately 20 ml of
fresh lysate directly onto a column of 5 ml Ni-NTA agarose (Qiagen
Production of NADH served as a read-out of enzyme activity. Final
30210) that had been preequilibrated with purification buffer con-
concentrations of assay components were as follows: 200 M UTP
taining 25 mM imidazole. The column was loaded at 0.5 ml/min;
(equivalent to the Km value); 20 mM Glc-1-P (equivalent to threeensuing washes and elutions were performed at 1.0 ml/min. The
times the Km value); 267 mU UDP-Glc dehydrogenase; 5.0 mM NAD;column was washed successively with purification buffer containing
80 mM Tris-HCl (pH 7.5); 5.0 mM MgCl2; and 0.05–0.1 mU UDP-25 mM imidazole (5 ml), 50 mM imidazole (20 ml), and 100 mM
HexNAc pyrophosphorylase. IC50 measurements were performed inimidazole (10 ml). Fractions (5 ml) were collected from the column
a similar fashion to those described previously. Initial rates and
during loading and washing. The 4-epimerase was eluted with purifi-
percent inhibition of enzyme activity were calculated as described
cation buffer containing 200 mM imidazole (20 ml); 2 ml fractions
for the 4-epimerase.
of the eluent were collected.
Column fractions were assayed for 4-epimerase activity using the
Spectrophotometric Assay for (1-4)same assay described above, with minor variations. Aliquots (10 l)
Galactosyltransferase Activityof column fractions were dispensed into a 96-well plate. A buffer
Activity of the (1-4)galactosyltransferase was monitored using acocktail containing the remaining assay reagents was prepared on
coupled enzyme assay as summarized below [53]:ice, incubated at room temperature for 10 min prior to use, and then
dispensed into the microplate at 90 l/well. Final concentrations UDP-Gal  -GlcNAc-OMe ((1-4)galactosyltransferase) →
of reagents were as follows: 1.0 mM UDP-Gal; 16 mU UDP-Glc UDP  Gal(1-4)GlcNAc-OMe
dehydrogenase; 1.25 mM -NAD; 125 mM potassium bicinate (pH UDP  phosphoenolpyruvate (pyruvate kinase) → UTP  pyruvate
8.5). Absorbance at 340 nm was monitored for 5 min. While enzyme Pyruvate  NADH (lactate dehydrogenase) → lactate  NAD
activity was observed in both the flow-through fractions and the 200
mM imidazole eluent, the former was nonspecific and was observed The disappearance of NADH, and thus galactosyltransferase activ-
even in the absence of UDP-Gal or UDP-Glc dehydrogenase. The ity, was monitored at 340 nm. Final concentrations of assay compo-
number of units of 4-epimerase present in active fractions was esti- nents were as follows: MgCl2, 10 mM; MnCl2, 5 mM; KCl, 50 mM;
mated by comparing rates to control samples containing known phosphoenolpyruvate (monocyclohexylammonium salt, Sigma P3637),
concentrations of the bacterial 4-epimerase. To these fractions, 1.5 mM; potassium bicinate (pH 8.5), 50 mM; NADH (Sigma 340-105),
glycerol and -NADwere added to final concentrations of 50% (vol/ 0.2 mM; -GlcNAc-OMe, 4 mM; pyruvate kinase (Sigma, P9136),
vol) and 4.0 mM, respectively. 4-Epimerase was stored immediately 150 mU; lactate dehydrogenase (Calbiochem 427217), 150 mU; (1-
at 20C, where it was stable for approximately 1 month. Glycerol 4)galactosyltransferase (Calbiochem 345649), 0.1 mU; UDP-Gal, 100
solutions of 4-epimerase were used in subsequent assays at dilu- M, the Km concentration. Assay components were assembled on
tions ranging from 10- to 50-fold, depending on the stock solution ice in the order listed, with the requisite amount of water added
concentration. Overall, we found the human 4-epimerase to be much first. Enzyme solutions and NADH were prepared fresh just prior
less stable than its bacterial counterpart; overnight dialysis to re- to the assay. It was important that the phosphoenolpyruvate be
move imidazole or freezing of aliquots in the absence of glycerol sufficiently buffered, as an acidic solution would cause decomposi-
both ablated enzyme activity. tion of the NADH. Normally, the phosphoenolpyruvate was prepared
as a 10	 stock solution in 10	 potassium bicinate. The pH of the
reaction mixture was measured prior to NADH addition. IC50 mea-Spectrophotometric Assay for UDP-Glc
surements were performed an analogous manner to that describedDehydrogenase Activity
for the 4-epimerase.Activity of the UDP-Glc dehydrogenase was monitored as described
by the equation below:
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